Pancreatic cancer clinical trials and accrual in the United States

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3432-3438

  Hoos, William A ^a   James, Porsha M ^a   Rahib, Lola ^a   Talley, Anitra W ^a   Fleshman, Julie M ^a   Matrisian, Lynn M ^a  

^a Pancreatic Cancer Action Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; HUMAN; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS ISLET CELL TUMOR; PATIENT DECISION MAKING; PHYSICIAN; PRIORITY JOURNAL; UNITED STATES; FEMALE; MALE; METHODOLOGY; PANCREATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; RESEARCH DESIGN; UNITED STATES;

EID: 84890468782     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.4823     Document Type: Conference Paper

References (29)

1. American Cancer Society: Cancer Facts and Figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
2. Eheman C, Henley SJ, Ballard-Barbash R, et al: Annual Report to the Nation on the Status of Cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118:2338-2366, 2012
3. Matrisian LM, Aizenberg R, Rosenzweig A: The alarming rise of pancreatic cancer deaths in the United States: Why we need to stem the tide today. Manhattan Beach, CA, Pancreatic Cancer Action Network, 2012. http://www.pancan .org/section-research/reports/pdf/incidence-report-2012.pdf
4. Wood LD, Hruban RH: Pathology and molecular genetics of pancreatic neoplasms. Cancer J 18:492-501, 2012
5. Feig C, Gopinathan A, Neesse A, et al: The pancreas cancer microenvironment. Clin Cancer Res 18:4266-4276, 2012
6. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
7. Sullivan KM, Kozuch PS: Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer. Cancer J 18:633-641, 2012
8. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
9. National Comprehensive Cancer Network: Pancreatic adenocarcinoma, 2012 (version 2.2012). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#pancreatic
10. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
11. Comis RL, Crowley J, Unger J, et al: Baseline study of patient accrual onto publicly sponsored U.S. cancer clinical trials: An analysis conducted for the Global Access Project of the National Patient Advocate Foundation. http://www.npaf.org/images/pdf/gap/sept-2006/cccg.pdf
12. Jemal A, Simard EP, Dorell C, et al: Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105:175-201, 2013
13. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002
14. Halfdanarson TR, Rabe KG, Rubin J, et al: Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727-1733, 2008
15. National Cancer Institute: Surveillance, Epidemiology, and End Results: Fast Stats. http://seer.cancer.gov/faststats
16. Wujcik D, Wolff SN: Recruitment of African Americans to national oncology clinical trials through a clinical trial shared resource. J Health Care Poor Underserved 21:38-50, 2010 (suppl)
17. Amgen: Amgen announces termination of ganitumab phase 3 study for futility in metastatic pancreatic cancer. http://www.amgen.com/media/media-pr-detail.jsp?releaseID-1723925
18. Von Hoff DD, Ervin TJ, Arena FP, et al: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). Presented at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-26, 2013
19. Lara PN Jr, Higdon R, Lim N, et al: Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19:1728-1733, 2001
20. Wright JR, Whelan TJ, Schiff S, et al: Why cancer patients enter randomized clinical trials: Exploring the factors that influence their decision. J Clin Oncol 22:4312-4318, 2004
21. Education Network to Advance Cancer Clinical Trials (ENACCT): A quality improvement program to improve cancer clinical trial recruitment, accrual, and retention: Lessons learned from the National Clinical Trials Pilot Breakthrough Collaborative. http://www.enacct.org/our-programs/national-learningcollaborative
22. American College of Surgeons: Cancer Program Standards 2012, Version 1.1: Ensuring patient-centered care. http://www.facs.org/cancer/coc/programstandards2012.html
23. National Cancer Institute: Cancer Bulletin 7: Special issue-Clinical trials enrollment. http://www.cancer.gov/ncicancerbulletin/051810/page1
24. Massett HA, Parreco LK, Padberg RM, et al: AccrualNet: Addressing low accrual via a knowledgebased, community of practice platform. J Oncol Pract 7:e32-e39, 2011
25. Cooper M, Poole K, Cameron DA, et al: Five fold increase in recruitment of cancer patients to National Institute for Health Research Cancer Research Network portfolio studies between 2001 and 2011. J Clin Oncol 30:404s, 2012 (suppl; abstr 6091)
26. Report of the Clinical Trials Working Group of the National Cancer Advisory Board: Restructuring the National Cancer Clinical Trials Enterprise. http://transformingtrials.cancer.gov/files/ctwgreport.pdf
27. National Cancer Institute: Gastrointestinal Steering Committee. http://transformingtrials.cancer.gov/steering-committees/gastrointestinal
28. Children's Oncology Group: The world's childhood cancer experts. http://www.childrensoncologygroup.org/index.php/aboutus
29. Multiple Myeloma Research Foundation: Powerful thinking advances the cure. http://www.themmrf.org